Potentially Inappropriate Medicines

Potentially Inappropriate Medicines (PIMs) refers to medications that, while legally available, may be harmful to certain patients due to age, comorbidities, or drug interactions. The Beers Criteria, updated by the American Geriatrics Society (AGS) in 2023, serves as the primary international reference for identifying these risks. In a corporate risk management context, PIMs represent a critical intersection of product liability and regulatory compliance. Companies must be closely closely monitoring these risks to comply with international standards like ISO 31000 and local regulations such as the Taiwan Pharmaceutical Act. Unlike prohibited substances, PIMs require a nuanced, patient-centric assessment, making them a moving target for risk-adjusted management. Effective identification is crucial for pharmaceutical companies to prevent adverse events that could lead to legal claims, regulatory fines, and damage to corporate reputation. The risk-adjusted-prescription-index (RAPI) is often used to quantify this risk-adjusted approach in clinical settings.

Implementation typically follows a three-step framework. Step 1: Risk Identification. Companies use tools like the Beers Criteria and STOPP/START criteria to categorize medications by risk-adjusted-index (RAI). Step 2: Risk Mitigation. This involves creating specific warnings for high-risk populations, implementing pharmacist-led-review protocols, and integrating clinical decision support systems (CDSS) into digital health platforms. Step 3: Monitoring and Reporting. Companies must track metrics such as the percentage of high-risk prescriptions per patient-year and the rate of adverse drug events (ADEs) reported. For example, a pharmaceutical company implementing these protocols might see a 30% reduction in adverse event-related claims within the first year. This proactive approach aligns with the Risk-Adjusted Intelligence (RAI)-based management-model, which prioritizes interventions where the risk-adjusted-benefit-ratio is lowest. This ensures that the company is not just reacting to incidents but actively preventing them through data-driven insights.

Taiwan enterprises face three primary challenges. First, regulatory ambiguity: the Taiwan Pharmaceutical Act does not explicitly define PIMs, leaving companies to self-regulate against international standards. The solution is to adopt the Beers Criteria as a baseline and monitor updates from the AGS. Second, data-siloing: patient-specific risk factors are often fragmented across different systems, making accurate PIMs assessment difficult. Companies should invest in integrated Electronic Health Record (EHR)-compatible systems that comply with the Taiwan Personal Data Protection Act. Third, personnel resistance: clinical staff may view risk-adjusted prescribing as an infringement on professional autonomy. Overcoming this requires change management strategies, including training programs and demonstrating the value of risk-adjusted prescribing in improving patient outcomes. A well-managed implementation program can be completed in 6 to 12 months, with measurable improvements in compliance and risk-adjusted-safety-index (RASI) scores.

Winners Consulting Services Co., Ltd. specializes in Potentially Inappropriate Medicines for Taiwan enterprises, delivering compliant management systems within 90 days. Free consultation: https://winners.com.tw/contact